Relationship between plasminogen activator inhibitor type-1 plasma levels and the lipoprotein(a) concentrations in non-insulin-dependent diabetes mellitus
- 1 July 1996
- journal article
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 33 (2) , 111-118
- https://doi.org/10.1016/0168-8227(96)01286-7
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patientsDiabetes, 1994
- Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1993
- The relationship of lipoprotein (a) to hemostasisCurrent Opinion in Lipidology, 1993
- Lipoprotein(a) and Diabetes: An updateDiabetes Care, 1993
- Lipoprotein(a) in Diabetic Patients and Normoglycemic Relatives in Familial NIDDMDiabetes Care, 1993
- Effects of Metformin on Insulin Resistance, Risk Factors for Cardiovascular Disease, and Plasminogen Activator Inhibitor in NIDDM Subjects: A study of two ethnic groupsDiabetes Care, 1993
- A rapid increase in lipoprotein (a) levels after ethanol withdrawal in alcoholic menLife Sciences, 1991
- Metformin Causes a Reduction in Basal and Post‐venous Occlusion Plasminogen Activator Inhibitor‐1 in Type 2 Diabetic PatientsDiabetic Medicine, 1991
- Lipoprotein (a) is not a metabolic product of other lipoproteins containing apolipoprotein BBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1979
- FIBRINOLYTIC EFFECT OF METFORMIN IN CORONARY-ARTERY DISEASEThe Lancet, 1965